Ticker Details
Galectin Therapeutics Inc. Galectin Therapeutics Inc is a clinical stage biopharmaceutical company. The company is engaged in drug research and development to create new therapies for fibrotic disease and cancer.
IPO Date:	October 1, 2002
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$191.48M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.14 | 3.91%
Avg Daily Range (30 D):	$0.11 | 3.53%
Avg Daily Range (90 D):	$0.18 | 3.90%

Institutional Daily Volume
Avg Daily Volume:	.35M
Avg Daily Volume (30 D):	.26M
Avg Daily Volume (90 D):	.43M

Trade Size
Avg Trade Size (Sh.):	252
Avg Trade Size (Sh.) (30 D):	108
Avg Trade Size (Sh.) (90 D):	136

Institutional Trades
Total Institutional Trades:	53
Avg Institutional Trade:	$1.96M
Avg Institutional Trade (30 D):	$.57M
Avg Institutional Trade (90 D):	$2.37M
Avg Institutional Trade Volume:	.4M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$3.59M
Avg Closing Trade (30 D):	$.57M
Avg Closing Trade (90 D):	$.57M
Avg Closing Volume:	856.99K

News

Nov 14, 2025 @ 1:00 PM Galectin Therapeutics Reports Financial Results fo... Source: Galectin Therapeutics

Jun 10, 2025 @ 12:56 PM Galectin Therapeutics to Host Virtual KOL Event to... Source: N/A

Jan 10, 2025 @ 1:00 PM Galectin Therapeutics to Present at the 2025 MASH-... Source: N/A

Aug 13, 2024 @ 12:00 PM Galectin Therapeutics Reports Financial Results fo... Source: N/A

Jun 4, 2024 @ 12:00 PM Galectin Therapeutics to Present at the European A... Source: Galectin Therapeutics Inc.

Financials
	TTM	Q3 2025	Q2 2025
Basic EPS	$-.59	$-.13	$-.12
Diluted EPS	$-.59	$-.13	$-.12
Revenue	$M	$M	$M
Gross Profit
Net Income / Loss	$-37.3M	$-8.18M	$-7.52M
Operating Income / Loss	$-29.15M	$-4.2M	$-4.63M
Cost of Revenue
Net Cash Flow	$M	$M	$7.69M
PE Ratio

Splits
Mar 23, 2012	1:6